Instrument Inactif

Communiqués Audentes Therapeutics, Inc.

Actions

US05070R1041

Recherche biotechnologique et médicale

Communiqués

15/01/20	AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	BU
16/12/19	AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	PR
03/12/19	AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/12/19	Audentes Therapeutics : Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics	BU
26/11/19	Audentes Therapeutics : to Participate in Upcoming Investor Conferences	BU
07/11/19	Audentes Therapeutics : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	BU
31/10/19	Audentes Therapeutics : to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019	BU
05/10/19	Audentes Therapeutics : Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society	BU
05/10/19	Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
01/10/19	Audentes Therapeutics : to Participate in Upcoming Investor Conferences	BU
30/09/19	Audentes Therapeutics : Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)	BU
07/09/19	Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/08/19	Audentes Therapeutics : to Participate in Upcoming Investor Conferences	PR
01/08/19	Audentes Therapeutics : to Participate in Upcoming Investor Conferences	PR
30/07/19	Audentes Therapeutics : to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019	PR
20/07/19	Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
08/06/19	Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
29/05/19	Audentes Therapeutics : Announces Changes to Senior Management Team	PR
08/05/19	Audentes Therapeutics : to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference	PR
30/04/19	Audentes Therapeutics : to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019	PR
27/04/19	Audentes Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
23/04/19	Audentes Therapeutics : Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility	PR
08/04/19	Audentes Therapeutics : Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy	PR